CA2704973A1 - Anti-factor b antibodies and their uses - Google Patents

Anti-factor b antibodies and their uses Download PDF

Info

Publication number
CA2704973A1
CA2704973A1 CA2704973A CA2704973A CA2704973A1 CA 2704973 A1 CA2704973 A1 CA 2704973A1 CA 2704973 A CA2704973 A CA 2704973A CA 2704973 A CA2704973 A CA 2704973A CA 2704973 A1 CA2704973 A1 CA 2704973A1
Authority
CA
Canada
Prior art keywords
antibody
factor
complement
amd
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2704973A
Other languages
English (en)
French (fr)
Inventor
Laura Deforge
Menno Van Lookeren Campagne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40344464&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2704973(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2704973A1 publication Critical patent/CA2704973A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2704973A 2007-11-08 2008-11-06 Anti-factor b antibodies and their uses Abandoned CA2704973A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US264807P 2007-11-08 2007-11-08
US61/002,648 2007-11-08
PCT/US2008/082621 WO2009061910A1 (en) 2007-11-08 2008-11-06 Anti-factor b antibodies and their uses

Publications (1)

Publication Number Publication Date
CA2704973A1 true CA2704973A1 (en) 2009-05-14

Family

ID=40344464

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2704973A Abandoned CA2704973A1 (en) 2007-11-08 2008-11-06 Anti-factor b antibodies and their uses

Country Status (15)

Country Link
US (4) US8158762B2 (2)
EP (1) EP2209807A1 (2)
JP (1) JP2011503094A (2)
KR (1) KR20100105587A (2)
CN (1) CN101918444A (2)
AR (1) AR069233A1 (2)
AU (1) AU2008323939A1 (2)
BR (1) BRPI0820343A2 (2)
CA (1) CA2704973A1 (2)
CL (1) CL2008003313A1 (2)
IL (1) IL205577A0 (2)
MX (1) MX2010005115A (2)
PE (1) PE20091022A1 (2)
TW (1) TW200927170A (2)
WO (1) WO2009061910A1 (2)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011003098A1 (en) 2009-07-02 2011-01-06 Musc Foundation For Research Development Methods of stimulating liver regeneration
TWI407953B (zh) * 2011-03-24 2013-09-11 Univ Kaohsiung Medical 用於調節補體因子ｂ（ｃｆｂ）表現的醫藥組合物
US9803005B2 (en) 2012-05-24 2017-10-31 Alexion Pharmaceuticals, Inc. Humaneered anti-factor B antibody
MY180626A (en) 2013-11-15 2020-12-03 Akebia Therapeutics Inc Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
EP3452510A4 (en) 2016-04-04 2020-01-15 Bioverativ USA Inc. ANTI-COMPLEMENT FACTOR BB ANTIBODIES AND USES THEREOF
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
EP4139350A4 (en) 2020-04-20 2024-04-24 Genzyme Corporation Humanized anti-complement factor bb antibodies and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
ATE135397T1 (de) 1988-09-23 1996-03-15 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
CA2488441C (en) 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
US20070123466A1 (en) * 2003-05-13 2007-05-31 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Method of treating recurrent miscarriages
BRPI0506629A (pt) * 2004-02-10 2007-05-02 Univ Colorado inibição do fator b, a via alternativa do sistema complemento e métodos relacionados
SG10201804008UA (en) * 2005-11-04 2018-06-28 Genentech Inc Use of complement pathway inhibitors to treat ocular diseases
NZ571791A (en) * 2006-03-08 2012-03-30 Archemix Llc Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders
JP5332064B2 (ja) * 2007-03-01 2013-11-06 ウェルスタット イムノセラピューティクス， エルエルシー 炎症により特徴付けられる疾患の治療

Also Published As

Publication number Publication date
US20180037667A1 (en) 2018-02-08
EP2209807A1 (en) 2010-07-28
WO2009061910A1 (en) 2009-05-14
US20090123469A1 (en) 2009-05-14
MX2010005115A (es) 2010-05-27
CL2008003313A1 (es) 2010-02-05
IL205577A0 (en) 2010-11-30
US20160024224A1 (en) 2016-01-28
CN101918444A (zh) 2010-12-15
US8158762B2 (en) 2012-04-17
AU2008323939A1 (en) 2009-05-14
KR20100105587A (ko) 2010-09-29
AR069233A1 (es) 2010-01-06
JP2011503094A (ja) 2011-01-27
TW200927170A (en) 2009-07-01
US20120230997A1 (en) 2012-09-13
BRPI0820343A2 (pt) 2017-08-22
PE20091022A1 (es) 2009-07-16

Similar Documents

Publication Publication Date Title
AU2008256835B2 (en) Prevention and treatment of complement-associated eye conditions
AU2008262048B2 (en) C3b antibodies and methods for the prevention and treatment of complement- associated disorders
US20180037667A1 (en) Anti-factor b antibodies and their uses
AU2017254945A1 (en) Prevention and treatment of complement-associated eye conditions
AU2013213753A1 (en) Prevention and treatment of complement-associated eye conditions
HK1139161B (en) Prevention and treatment of complement- associated eye conditions

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20141106